ARS Pharmaceuticals (SPRY) Cash & Current Investments (2020 - 2026)

ARS Pharmaceuticals (SPRY) has 7 years of Cash & Current Investments data on file, last reported at $201.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments fell 27.11% year-over-year to $201.0 million; the trailing twelve-month figure through Mar 2026 stood at $201.0 million (down 27.11% YoY), and the FY2025 full-year result was $245.0 million, down 21.98% from the prior year.
• Cash & Current Investments declined to $201.0 million in Q1 2026, from $245.0 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $314.0 million in Q4 2024 to a low of $201.0 million in Q1 2026.
• A 5-year average of $250.1 million and a median of $252.2 million in 2023 frame the typical range for Cash & Current Investments.
• Peak annual rise in Cash & Current Investments reached 356.82% in 2022, while the deepest fall reached 32.16% in 2022.
• Tracing SPRY's Cash & Current Investments over 5 years: stood at $274.4 million in 2022, then decreased by 16.77% to $228.4 million in 2023, then jumped by 37.51% to $314.0 million in 2024, then fell by 21.98% to $245.0 million in 2025, then declined by 17.97% to $201.0 million in 2026.
• Business Quant data shows SPRY's Cash & Current Investments at $201.0 million in Q1 2026, $245.0 million in Q4 2025, and $288.2 million in Q3 2025.